For people at risk of type 1 diabetes, there's remarkable news: a groundbreaking drug called teplizumab has just been approved for use on the NHS in England and Wales, offering patients the chance to delay the onset of the disease by up to three years.

Teplizumab works by slowing the early stages of type 1 diabetes, giving people precious time before symptoms appear. Those involved in the approval process have called it an "incredible moment" in diabetes care—a significant step forward for the thousands of families dealing with this autoimmune condition. The drug represents a new frontier in preventative medicine, shifting focus from managing disease after it strikes to potentially intercepting it before it fully develops. Read the full story →

Today's takeaway: Medical breakthroughs that prevent disease rather than just treat it offer hope to millions—and this approval shows that future is arriving now.